Gilead’s BIC LEN HIV Results Highlight Valuation Gap And Future Potential
Make better investment decisions with Simply Wall St’s easy, visual tools that give you a competitive edge. Gilead…
Liver Drug Approval and Pipeline Data Could Be a Game Changer for Gilead Sciences (GILD)
In recent weeks, Gilead Sciences announced Health Canada’s conditional approval of LYVDELZI (seladelpar) for primary biliary cholangitis, and…
Gilead Sciences (GILD) Profit Margin Surge Reinforces Bullish Narratives on Operational Turnaround
Gilead Sciences (GILD) delivered a net profit margin of 27.9%, a sharp turnaround from just 0.4% a year…
Greed Is a Hell of a Drug
On Sept. 24, the California-based multinational corporation Gilead Sciences announced it would lower the price of lenacapavir — a…